Gsk (GSK) Short-term Investments (2009 - 2026)

Gsk's Short-term Investments history runs 18 years deep, the most recent figure standing at -$210.6 million for Q2 2026.

• In Q2 2026, Short-term Investments fell 178.95% year-over-year to -$210.6 million; the TTM figure through Jun 2026 stood at -$210.6 million (down 178.95% YoY), while the FY2025 annual figure was $159.5 million, up 14.5% from the prior year.
• Short-term Investments for Q2 2026 stood at -$210.6 million, up from -$258.9 million in the prior quarter.
• The five-year high for Short-term Investments was $313.1 million in Q3 2024, with the low at -$383.0 million in Q3 2022.
• The 5-year median for Short-term Investments is $125.9 million (2022), against an average of $36.7 million.
• The sharpest annual moves came in 2023 and 2026: Short-term Investments soared 639.2% in 2023, then plunged 316.33% in 2026.
• Gsk's Short-term Investments stood at $78.6 million in 2022, then surged by 105.32% to $161.3 million in 2023, then fell by 13.29% to $139.9 million in 2024, then climbed by 15.05% to $161.0 million in 2025, then plunged by 230.88% to -$210.6 million in 2026.
• Business Quant data shows GSK's Short-term Investments at -$210.6 million in Q2 2026, -$258.9 million in Q1 2026, and $161.0 million in Q4 2025.